Drug Solubilization Behavior During in Vitro Digestion of Suspension Formulations of Poorly Water-soluble Drugs in Triglyceride Lipids

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2004 Mar 23

PMID 15032306

Citations 28

Authors

Ann Marie Kaukonen

Ben J Boyd

William N Charman

Christopher J H Porter

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to characterize the solubilization and precipitation characteristics of a range of poorly water-soluble drugs during the in vitro digestion of long-chain or medium-chain triglyceride (TG) lipid suspension formulations.

Methods: TG suspensions of model drugs (present at double their equilibrium solubilities in the respective lipid) were digested in vitro and the drug solubilization and precipitation pattern in the resulting digests analyzed.

Results: For griseofulvin, diazepam, and danazol, solubilization of the small mass of drug originally presented in the TG lipid was efficient with only a small proportion of the dose precipitating and being recovered in the pellet phase after digestion of the TG lipid. For the more lipophilic and lipid-soluble drugs (cinnarizine, halofantrine), in which higher drug loadings were possible, significant enhancement in drug solubilization in the postdigestion aqueous phase was not apparent compared with simple TG lipid solutions.

Conclusions: Suspensions of drugs, which are poorly soluble in water and TG lipid, may prove beneficial as the relatively high solubilizing capacity of the colloidal phases produced on TG digestion will likely exceed the mass of drug that could have been administered as a simple lipid solution. However, for more lipid-soluble drugs, suspension formulations may offer little benefit as sufficiently high drug loadings can otherwise be achieved with simple solution formulations that still provide for adequate solubilization after TG digestion.

Citing Articles

Simulation of Antral Conditions for Estimating Drug Apparent Equilibrium Solubility after a High-Calorie, High-Fat Meal.

Reppas C, Chorianopoulou C, Karkaletsi I, Dietrich S, Bakolia A, Vertzoni M Mol Pharm. 2025; 22(2):871-881.

PMID: 39811984 PMC: 11795529. DOI: 10.1021/acs.molpharmaceut.4c01038.

Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD).

Moghtadaie A, Mahboobi H, Fatemizadeh S, Kamal M EXCLI J. 2023; 22:946-974.

PMID: 38023570 PMC: 10630531. DOI: 10.17179/excli2023-6420.

Lipid Compositions in Infant Formulas Affect the Solubilization of Antimalarial Drugs Artefenomel (OZ439) and Ferroquine during Digestion.

Salim M, Ramirez G, Peng K, Clulow A, Hawley A, Ramachandruni H Mol Pharm. 2020; 17(7):2749-2759.

PMID: 32574056 PMC: 7341521. DOI: 10.1021/acs.molpharmaceut.0c00475.

Comparisons of in vitro Fick's first law, lipolysis, and in vivo rat models for oral absorption on BCS II drugs in SNEDDS.

Ye J, Wu H, Huang C, Lin W, Zhang C, Huang B Int J Nanomedicine. 2019; 14:5623-5636.

PMID: 31440045 PMC: 6664859. DOI: 10.2147/IJN.S203911.

A Proof of Concept for 3D Printing of Solid Lipid-Based Formulations of Poorly Water-Soluble Drugs to Control Formulation Dispersion Kinetics.

Vithani K, Goyanes A, Jannin V, Basit A, Gaisford S, Boyd B Pharm Res. 2019; 36(7):102.

PMID: 31098846 DOI: 10.1007/s11095-019-2639-y.

References

Ginsburg C, McCracken Jr G, Petruska M, Olsen K . Effect of feeding on bioavailability of griseofulvin in children. J Pediatr. 1983; 102(2):309-11. DOI: 10.1016/s0022-3476(83)80549-6. View

Mueller E, Kovarik J, van Bree J, Grevel J, Lucker P, Kutz K . Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res. 1994; 11(1):151-5. DOI: 10.1023/a:1018922517162. View

Kossena G, Boyd B, Porter C, Charman W . Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. J Pharm Sci. 2003; 92(3):634-48. DOI: 10.1002/jps.10329. View

Gershanik T, Benita S . Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm. 2000; 50(1):179-88. DOI: 10.1016/s0939-6411(00)00089-8. View

Charman W, Rogge M, Boddy A, Berger B . Effect of food and a monoglyceride emulsion formulation on danazol bioavailability. J Clin Pharmacol. 1993; 33(4):381-6. DOI: 10.1002/j.1552-4604.1993.tb04673.x. View

Charman W, Porter C, Mithani S, Dressman J . Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci. 1997; 86(3):269-82. DOI: 10.1021/js960085v. View

Khoo S, Prankerd R, Edwards G, Porter C, Charman W . A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs. J Pharm Sci. 2002; 91(3):647-59. DOI: 10.1002/jps.10045. View

Cistola D, Hamilton J, Jackson D, Small D . Ionization and phase behavior of fatty acids in water: application of the Gibbs phase rule. Biochemistry. 1988; 27(6):1881-8. DOI: 10.1021/bi00406a013. View

Staggers J, Hernell O, Stafford R, Carey M . Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 1. Phase behavior and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. Biochemistry. 1990; 29(8):2028-40. DOI: 10.1021/bi00460a011. View

10.

Porter C, Charman W . In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev. 2001; 50 Suppl 1:S127-47. DOI: 10.1016/s0169-409x(01)00182-x. View

11.

Humberstone A, Porter C, Charman W . A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J Pharm Sci. 1996; 85(5):525-9. DOI: 10.1021/js950472p. View

12.

Ladas S, Isaacs P, Murphy G, Sladen G . Comparison of the effects of medium and long chain triglyceride containing liquid meals on gall bladder and small intestinal function in normal man. Gut. 1984; 25(4):405-11. PMC: 1432336. DOI: 10.1136/gut.25.4.405. View

13.

Kaukonen A, Boyd B, Porter C, Charman W . Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations. Pharm Res. 2004; 21(2):245-53. DOI: 10.1023/b:pham.0000016282.77887.1f. View

14.

Pouton C . Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci. 2000; 11 Suppl 2:S93-8. DOI: 10.1016/s0928-0987(00)00167-6. View

15.

Milton K, Edwards G, Ward S, Orme M, Breckenridge A . Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol. 1989; 28(1):71-7. PMC: 1379972. DOI: 10.1111/j.1365-2125.1989.tb03507.x. View

16.

Hernell O, Staggers J, Carey M . Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry. 1990; 29(8):2041-56. DOI: 10.1021/bi00460a012. View

17.

Armand M, Borel P, Pasquier B, Dubois C, Senft M, Andre M . Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum. Am J Physiol. 1996; 271(1 Pt 1):G172-83. DOI: 10.1152/ajpgi.1996.271.1.G172. View

18.

Bates T, Sequeria J . Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans. J Pharm Sci. 1975; 64(5):793-7. DOI: 10.1002/jps.2600640513. View

19.

Aungst . P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv Drug Deliv Rev. 2000; 39(1-3):105-116. DOI: 10.1016/s0169-409x(99)00022-8. View

20.

Sek L, Porter C, Charman W . Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis. J Pharm Biomed Anal. 2001; 25(3-4):651-61. DOI: 10.1016/s0731-7085(00)00528-8. View